VANCOUVER, British Columbia and MENLO PARK, Calif., June 25, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of… Read More
June 13, 2019 (Ottawa) The Stem Cell Network is pleased to launch a new national research funding competition comprised of four translational research programs in stem cell and regenerative medicine. The… Read More
– AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production – Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June… Read More
WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat… Read More
WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat… Read More
